EGFR and non-small cell lung carcinoma: DP‐V‐4 showed superior activity compared with that of single‐agent degraders in preclinical models, where it displayed over 70% tumor growth inhibition, particularly in osimertinib‐resistant EGFR‐mutant NSCLC, demonstrating the potential of this strategy to deplete redundant oncogenic pathways (Maity et al. 2023).